Every physician-led specialty in America has been losing the same fight for thirty years. Hospitals buying out practices, insurance companies squeezing reimbursement, private equity rolling up what's left. Cardiology went majority hospital-employed. Primary care fell below 50% independent a decade ago. Orthopedic surgery crossed below 60% long before that. Anesthesia is 18.8% owned by private equity or public companies. Fertility medicine has one of the highest PE ownership rates in healthcare. Dermatology has seen over 245 practices acquired by PE platforms since 2012.

One specialty kept winning.

The American Medical Association's 2024 Physician Practice Benchmark Survey, released by Dr. Carol Kane in early 2025, contains a number that nobody outside ophthalmology is talking about: 70.4% of ophthalmologists still own their practices. It's the highest private-practice rate of any medical specialty in the United States. The rest of American medicine went one way; ophthalmology went the other. The question worth asking isn't whether ophthalmology got lucky but what's structurally different about this specialty that let physician ownership survive when everything around it collapsed, because understanding the answer changes how you think about where the category goes next.

What That Number Actually Means

The AMA's Physician Practice Benchmark Survey is the most comprehensive analysis of how American physicians organize their working lives, sampling across specialties, geographies, and practice sizes. The survey has tracked physician practice ownership patterns since 2012, and the data shows a consistent decline across nearly every specialty. Orthopedic surgery ranks second at 54.0%, ENT sits at approximately 53.8%, and no other surgical specialty breaks 50%. Ophthalmology sits more than 16 percentage points above the next-closest specialty. The overall US physician private-practice rate in 2024 was 42.2%, down from 60.1% in 2012, with hospital or corporate employment now accounting for 77.6% of American physicians and private equity owning or controlling 6.5% of physician practices nationally. Ophthalmology's position isn't just resilience; it's an outlier that defies every consolidation trend that reshaped American medicine over the last fifteen years, and the structural reasons behind that outlier explain why the specialty is about to become one of the last remaining opportunities in American healthcare for capital that wants to own real operating businesses.

The Consolidation That Didn't Happen

Private equity discovered ophthalmology in 2017. By 2024, roughly 245 ophthalmology practices had been acquired by PE-backed platforms, around 40 MSOs now operate in the specialty, and industry estimates place single-digit percent of practicing ophthalmologists inside PE-owned groups. That's not nothing, but it's also nowhere close to what PE did to dermatology, dental, veterinary, or gastroenterology in the same timeframe. For comparison: dental service organizations controlled 7.2% of US dental practices in 2015, by 2024 DSOs controlled 16.1%, and L.E.K. Consulting projects roughly 39% DSO share by 2026. Veterinary consolidation is farther along, with approximately 50% of veterinary practice revenue flowing through corporate-owned structures. Dermatology has seen 245+ practices acquired and at least 35-40 PE platforms operating in the space.

Ophthalmology never got rolled up that way. PE tried: platforms like EyeCare Partners, EyeSouth Partners, Vision Innovation Partners, American Vision Partners, and Unifeye Vision all formed between 2017 and 2019 with the explicit goal of scaling ophthalmology consolidation into a category-dominant asset class. It didn't happen. The category resisted, and the structural reasons explain why it resisted in ways that weren't true of the specialties that did consolidate.

The Surgeon Identity That Wouldn't Dissolve

Ophthalmologists spend the longest training pipeline in medicine after neurosurgery: four years of undergraduate education, four years of medical school, a one-year internship, three to four years of ophthalmology residency, and for subspecialists, one to two additional fellowship years in cornea, retina, glaucoma, oculoplastics, or pediatric ophthalmology. By the time an ophthalmologist completes training, they're typically 32-35 years old and have been moving toward the same identity for fifteen years. That identity isn't "employee." It's "the ophthalmologist." Survey data from ophthalmology training programs shows this operator-identity pattern consistently: a 2025 survey of vitreoretinal fellows found that 81.4% flagged autonomy and job-security concerns as primary reasons to avoid PE-owned practices, and a parallel survey of ophthalmology trainees found 78% would not consider employment at a PE-backed practice.

When physicians hold that strong of an identity attachment to independence, consolidators face a structural problem: you can buy a practice but you can't buy the next generation of surgeons who'll run it, because the workforce doesn't want to work for you. Every other specialty faced some version of this, but ophthalmology's training pipeline produces a particularly concentrated version. The people who complete seven to nine years of post-undergraduate training to perform microsurgery on the eye are self-selected for autonomy and mastery; they didn't sign up for a corporate operator to manage their schedule, their patients, or their technique. That identity didn't dissolve when PE arrived. It hardened.

Economics That Hold up Under Physician Ownership

Most consolidation-vulnerable specialties share one characteristic: the economics broke before the consolidation started. Primary care has been structurally underpaid by insurers for two decades, which is why hospital employment absorbed it. Anesthesia fee compression made independent anesthesia groups unsustainable against staffing company scale. Dental and veterinary economics were squeezed by equipment costs and tech overhead that small practices couldn't absorb. Ophthalmology's economics are different.

Cataract surgery generated approximately 3.8 million procedures in the US in 2023, Medicare covers the majority of the cataract population, and the procedure is one of the most commonly performed surgeries in American medicine. Cataract volume has grown roughly 40% since 2008 driven by demographic aging, and projections from CMS and the National Eye Institute suggest continued growth through 2040. Retina subspecialty practice generates a similar demographic tailwind: age-related macular degeneration affected 19.83 million Americans 40+ in 2019, with 1.49 million cases classified as vision-threatening per JAMA Ophthalmology modeling, and AMD prevalence is projected to reach 21.3 million globally by 2050. Diabetic retinopathy volume is expected to grow from roughly 5.5 million US cases in 2005 to 16 million by 2050. US glaucoma prevalence was 2.71 million cases in 2011 and is projected to reach 7.32 million by 2050 per the Vajaranant et al. modeling published in Investigative Ophthalmology and Visual Science.

A well-run solo ophthalmology practice generates $1.0-1.5 million in annual revenue, and retina-heavy clinics generate $3M+ per FTE ophthalmologist (though drug pass-through economics distort the margin picture at that specialty). Overhead rates sit at 52% for the top quartile of practices, 58% for the median, and 67% for the bottom quartile per American Academy of Ophthalmology AAOE benchmarking data. After physician compensation, cash flow margins in well-run groups typically run 15-25%, and ambulatory surgery center economics add another layer on top: the facility fee for a Medicare cataract case in 2025 is approximately $1,371, roughly 2.4 times the physician professional fee, and practices that own their ASCs capture both revenue streams.

These numbers explain why ophthalmology stayed independent when other specialties couldn't: the underlying business works, patient volume grows with demographics, and unit-price reimbursement has compressed (cataract 66984 payment fell from approximately $1,200 in 1982 to $521.75 in 2025) but procedure volume growth, subspecialty pricing power, and ASC economics offset most of the unit-price decline at the practice level. Compensation data backs this up. Medscape's 2025 ophthalmology compensation report put average ophthalmologist pay at $409,000 in 2024 (flat against 2023), Doximity's figure is closer to $477,000, and self-reported data from independent-ownership ophthalmologists ranges $544,000 to $692,000 depending on subspecialty and ownership structure. Owner ophthalmologists running $2M-plus practices commonly take home $500,000-$700,000 after expenses and retirement funding. Those economics aren't explosive: a $2M practice generates roughly $500K of owner cash flow that scales linearly, and that profile doesn't match the growth requirements that PE fund returns require, but it compounds reliably across decades, which is exactly what patient-capital operators look for.

The Physician-Owner Who's Already Winning

This is the structural reason that's most often missed. Most specialties consolidated because independent-practice economics were too weak to compete against hospital or corporate aggregation. Primary care doctors sold to hospitals because independent primary care was losing money. Dermatologists sold to PE because they were cash-poor despite revenue growth. Dental practices sold to DSOs because small-practice economics couldn't absorb the equipment and tech overhead. Ophthalmology is the opposite case.

A mature ophthalmology practice owner generates personal income in the $500K-$700K range, with equity building in the practice itself, typical ASC ownership participation, and potentially owned commercial real estate generating 5-8% cap rate rent. A 30-year career produces $15M-$30M in practice revenue, $9M-$21M in personal income, and multi-million-dollar terminal practice equity. Compared to that, the PE offer has structurally underperformed. A typical ophthalmology PE acquisition offers 5-6x EBITDA on the practice, with physician compensation cut 20-40% post-acquisition, and retention equity paying out in a liquidity event that often doesn't materialize on schedule. The physician who sells to PE trades durable long-term cash flow for a one-time payment and becomes an employee in a practice they previously owned. For a 45-year-old ophthalmologist with 20 years of runway left, that math doesn't work; for a 65-year-old ophthalmologist with limited succession options, it sometimes does. That's why PE has found traction primarily among older ophthalmologists approaching retirement without successor physicians lined up.

Ophthalmology's independent-practice economics are strong enough that most ophthalmologists don't need to sell. The ones who do sell are typically selling because of a succession problem, not an economic problem, and that's a different kind of transaction than what drove consolidation in dermatology, dental, or vet. It produces a different outcome.

The Outlier Math

Consolidation pressure compounds over time. Once a specialty passes a consolidation threshold, it rarely reverses: cardiology and primary care crossed those thresholds decades ago, and dental, vet, and derm are crossing them now. Ophthalmology hasn't. The combination of operator-identity resistance, durable unit economics, and successful physician-owner outcomes has held the specialty's independent ownership structure intact longer than any comparable category.

That's the outlier, and for capital that wants to own real operating businesses for the long term, that outlier is the opportunity. The independence rate isn't just a snapshot of where ophthalmology is today; it's evidence that the specialty has structural properties that make physician-led ownership durable in ways that don't apply to most of American medicine. The right capital structure for participating in ophthalmology isn't the structure that worked for the specialties that did consolidate; it's the structure that matches the way ophthalmology actually operates. Patient capital. Permanent-hold. Physician-led. Built to compound across decades rather than exit in a fund cycle. The data tells us the specialty is structurally intact, and what capital does next determines whether that stays true for another generation.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com